Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,957 total articles

Autozi Internet Technology (Global) Ltd. Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities

Autozi Internet Technology (Global) Ltd. Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities

Autozi Internet Technology (Global) Ltd. announced that it received a notification from Nasdaq for failing to meet the minimum Market Value of Listed Securities of $50 million over the past 30 consecutive business days. The company has until September 21, 2026, to regain compliance or face potential delisting. The notification does not impact curre…

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MoonLake Immunotherapeutics reported Week 40 results from its Phase 3 VELA clinical trials evaluating sonelokimab in adults with moderate-to-severe hidradenitis suppurativa (HS). The data demonstrated continued improvement with 62% of patients achieving HiSCR75 and up to 32% achieving HiSCR100 responses, alongside significant quality of life enhanc…

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Kymera Therapeutics announced positive results from its BroADen Phase 1b trial of KT-621, a novel oral STAT6 degrader, in patients with moderate-to-severe atopic dermatitis. The data showed significant biological and clinical improvements with a favorable safety profile. Ongoing Phase 2b trials in atopic dermatitis and asthma are expected to provid…

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Arcutis Biotherapeutics announced new positive Phase 2 results from the INTEGUMENT-INFANT trial showing that ZORYVE (roflumilast) cream 0.05% is effective and well tolerated in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. Caregivers reported rapid itch improvement and multiple clinical endpoints demonstrated…

Osisko Development Reports Fourth Quarter and Year-End 2025 Results

Osisko Development Reports Fourth Quarter and Year-End 2025 Results

Osisko Development Corp. announced its financial and operational results for Q4 and full-year 2025, highlighting approximately CAD 422.3 million in cash, sales of nearly 4,000 ounces of gold from small-scale activities at the Tintic Project, and significant advancement in the Cariboo Gold Project's infill drilling and pre-construction activities. T…

Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency

Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency

Rocket Lab successfully launched its 85th mission, marking the first dedicated launch for the European Space Agency (ESA) using its Electron launch vehicle. The 'Daughter Of The Stars' mission delivered ESA's Celeste satellites to low Earth orbit to demonstrate enhanced satellite navigation alongside Europe's Galileo constellation. This success und…

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis Inc. reported positive Phase 3 results for envudeucitinib, its oral TYK2 inhibitor, demonstrating robust skin clearance, rapid improvements in quality of life and itch relief, and a favorable safety profile in patients with moderate-to-severe plaque psoriasis. Data from two pivotal trials ONWARD1 and ONWARD2 indicate sustained efficacy throu…

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Priovant Therapeutics, a Roivant company, reported positive Phase 3 trial results for brepocitinib in dermatomyositis, showing statistically significant improvements over placebo in multiple efficacy endpoints including muscle strength, skin disease, physical function, and corticosteroid reduction. Results were published in the New England Journal …

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Biogen announced positive Phase 2 results from the AMETHYST study for litifilimab, an investigational monoclonal antibody targeting BDCA2, demonstrating statistically significant improvement in skin disease activity in patients with cutaneous lupus erythematosus (CLE). These consistent positive results, along with a favorable safety profile and FDA…

Fusion Fuel Highlights Royal Uranium’s 2% NSR on Two Mineral Claims held by the Shea Creek Joint Venture, One of Canada’s Largest Undeveloped Uranium Projects in the Athabasca Basin

Fusion Fuel Highlights Royal Uranium’s 2% NSR on Two Mineral Claims held by the Shea Creek Joint Venture, One of Canada’s Largest Undeveloped Uranium Projects in the Athabasca Basin

Fusion Fuel Green PLC announced details on its anticipated 2% Net Smelter Return (NSR) royalty on two mineral claims within the Shea Creek Joint Venture, part of a 16-uranium-royalty portfolio expected to be acquired through its pending transaction with Royal Uranium Inc. The Shea Creek project hosts significant undeveloped uranium resources in Can…

Case IH Celebrates American Farmers At The White House

Case IH Celebrates American Farmers At The White House

CNH Industrial's Case IH brand showcased its iconic Heartland Magnum tractor on the White House South Lawn during a presidential event celebrating American agriculture. This one-of-a-kind patriotic tractor symbolizes nearly four decades of manufacturing excellence and CNH's strong commitment to US farming and innovation. CNH Industrial, with a larg…

Magna Posts 2025 Annual Report

Magna Posts 2025 Annual Report

Magna International Inc., a leading global automotive supplier, has published its 2025 Annual Report, including financial statements and management analysis. The company announced its 2026 Annual Meeting of shareholders will be held virtually on May 4, 2026. Magna's reports are accessible on their website and regulatory agencies in Canada and the U…

Electra Restarts Construction and Reports 2025 Financial Results

Electra Restarts Construction and Reports 2025 Financial Results

Electra Battery Materials Corporation announced a successful recapitalization and the restart of construction on its cobalt sulfate refinery in Ontario, with a $73 million board-approved budget targeting mechanical completion in mid-2027 and commercial production by late 2027. The company strengthened its balance sheet via debt-to-equity conversion…

Manhattan Bridge Capital, Inc. Reports 2025 Results

Manhattan Bridge Capital, Inc. Reports 2025 Results

Manhattan Bridge Capital, Inc., a Nasdaq-listed firm specializing in short-term secured real estate loans, reported net income of approximately $5.11 million for 2025, down 8.6% from 2024 due to lower interest income and a decrease in loan originations. Revenue declined by 10.6% reflecting a contraction in loans receivable and slowed loan originati…

Preliminary Results for the Year Ended 31 December 2025

Preliminary Results for the Year Ended 31 December 2025

Biodexa Pharmaceuticals PLC, a NASDAQ-listed clinical-stage biopharmaceutical company specializing in gastrointestinal cancers, announced its audited preliminary results for the year ended December 31, 2025. Key developments include progress in the Phase 3 Serenta trial of eRapa for Familial Adenomatous Polyposis, initiation of a Phase 2a study of …

E-Power Inc. and Raytel Electronics Announce Strategic Alliance to Launch Next-Generation 800G and 1.6T High-Speed Optical Modules for U.S. AI Data Centers

E-Power Inc. and Raytel Electronics Announce Strategic Alliance to Launch Next-Generation 800G and 1.6T High-Speed Optical Modules for U.S. AI Data Centers

E-Power Inc. has announced a strategic alliance with Raytel Electronics to co-develop and launch next-generation 800G and 1.6T high-speed optical modules targeted at the North American AI data center market. By integrating Raytel's optical tech with E-Power's power solutions, the companies aim to deliver optimized connectivity and energy management…

Atlanta Braves, Gray Media to Simulcast 25 Regular Season Games on Free, Local Over-the-Air Television Stations Across the Southeast

Atlanta Braves, Gray Media to Simulcast 25 Regular Season Games on Free, Local Over-the-Air Television Stations Across the Southeast

The Atlanta Braves and Gray Media have entered a multi-year agreement to simulcast 25 regular season Braves games on Gray's local television stations across the Southeast, expanding access to free over-the-air broadcasts alongside the Braves' own BravesVision platform. Gray's Raycom Sports will provide production services for BravesVision games. Th…

VEON Reinforces Alignment with Shareholder Value Creation

VEON Reinforces Alignment with Shareholder Value Creation

VEON Ltd. highlights strong alignment between management and shareholders through meaningful insider ownership exceeding 1.8% and ongoing disciplined capital allocation, including a substantial $100 million annual share buyback target. The company continues to execute its digital operator strategy across five frontier markets, focusing on sustainab…

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

LB Pharmaceuticals announced new positive data from the Phase 2 NOVA-1 trial showing that LB-102, a novel benzamide antipsychotic candidate, directly improves cognitive performance in patients with acute schizophrenia. These findings, presented at the 2026 Schizophrenia International Research Society Congress, support ongoing Phase 3 and additional…